Hospitals Sue to Stop the 340B Rebate Cash Switch

The American Hospital Association sued the Department of Health and Human Services on October 9, 2026, to block a 340B rebate pilot due January 1, 2027. The Maine Hospital Association and four safety-net hospitals joined the case in the U.S. District Court for the District of Maine.

Hospitals would still get the 340B ceiling price on the listed drugs. They would buy at wholesale acquisition cost, send claims after they dispense, and collect the discount only when a manufacturer pays a rebate.

Hospitals File Again in Maine Federal Court

The new case is American Hospital Association et al. v. Kennedy et al., No. 1:26-cv-00515. It names HHS Secretary Robert F. Kennedy Jr., the Health Resources and Services Administration, and HHS. Plaintiffs also asked for a temporary restraining order the same day, aiming to freeze the January start.

The four hospitals are Eastern Maine Medical Center in Maine, Unity Medical Center in North Dakota, Dallas County Medical Center in Arkansas, and Nathan Littauer Hospital and Nursing Home in New York, all community providers that buy 340B drugs. Their complaint for injunctive relief says HRSA again failed to count what a rebate desk would cost the hospitals that have to run it.

Hospital analyses put office and paperwork costs at more than $1 billion in annual costs, far above HHS’s $537 million figure. The association says that HHS figure skips rebate reconciliation, startup costs, cash-flow burdens, and the loss of cost-of-goods-sold benefits. HRSA took more than 2,400 comments on the second version, including hospitals that described a “catastrophic impact” in detail.

When the government makes a change of this magnitude, it must fully consider what it will mean for the patients and communities that rely on 340B hospitals every day.

Steve Walsh, president and CEO, American Hospital Association, Oct. 9, 2026 statement

Walsh also said member hospitals offered other ways to handle transparency and program integrity without the same price tag, and that those costs “cannot be treated as afterthoughts.” The 2025 version died in the same district after a judge and the First Circuit said HHS had not faced up to the cost of making hospitals operate a rebate system.

Which Drugs Are on the Rebate List?

HRSA has posted 10 manufacturers’ approved rebate plans for a January 1, 2027 start, all on the Beacon Rebate Model Platform. The products are drugs on the Medicare Drug Price Negotiation selected lists for 2026 and 2027, sold to 340B providers no matter who pays. Other 340B drugs would still be bought at the upfront ceiling.

APPROVED 340B REBATE PLANS FOR JANUARY 2027

That public table lists 21 product names, counting extended-release versions separately. The 2025 pilot covered 10 drugs. The revised design opened the door to the two-year Medicare negotiation set, a larger pool often described as about 25 products, and 10 companies then got plans approved. High-cost oral heart, cancer, diabetes, and lung drugs sit on the list, which is why a small share of 340B line items can still tie up a lot of cash.

Paying Wholesale First, Collecting the Discount Later

Under the long-standing 340B method, a covered hospital buys at the ceiling and the discount is in the invoice. Under the pilot, the same hospital still uses its 340B wholesaler account, but the account is loaded at wholesale acquisition cost. The rebate, paid at the unit level, is wholesale cost minus the 340B ceiling on the day the drug is dispensed.

HOW THE REBATE CLOCK RUNS

• The purchase: The hospital orders the listed drug through its existing 340B wholesaler account at wholesale acquisition cost, not through a separate GPO or WAC-only account if it wants a rebate.
• The claim window: After a dispense, the hospital has 45 calendar days to send claims data through Beacon, with a chance to resubmit if a file comes back incomplete.
• The pay clock: The manufacturer must pay the rebate or issue a documented denial within 10 calendar days of a complete submission; an incomplete file restarts that 10-day clock.
• The transition pad: Plans must allow up to 2 unreplenished accumulated packages and a 15-calendar-day grace period before the start date, with claims still due 45 days from dispense.
• The bill for the pipe: Manufacturers, not hospitals, must bear the cost of the IT platform used to send the data.

The pharmacy vendor VytlOne calculated that a rebate model limited to the 10 drugs in the 2026 Medicare negotiation round would move between $2.34 million and $4.67 million a year through the average 340B hospital’s cash account. That figure is working capital, the money sitting in inventory and receivables, not the interest charged on it.

An IQVIA white paper put rebate-related interest costs as marginal for disproportionate-share hospitals, other hospitals, and federal grantees in a 10-drug model. HHS has also said that payment to wholesalers would, in most cases, come due after the manufacturer rebate arrives, which would shrink the float if wholesaler terms are long enough and rebates actually land in 10 days.

Hospitals arguing the other side are not mainly fighting that interest math. They are counting a new claims operation, denied or late rebates that turn a former discount into a collections file, and accounting hits when drugs no longer sit in inventory at the 340B ceiling. Those are different costs from a small interest line on a 10-day receivable.

Less Than Two Weeks of Cash in Maine

Jeff Austin, president of the Maine Hospital Association, said Maine hospitals “already operate with an average of less than two weeks cash-on-hand,” and that the rebate model would put care for the most vulnerable patients at risk. Guy Hudson, MD, president and CEO of Northern Light Health, said the shift would put financial pressure on hospitals and clinics that use 340B savings to support patient care, and that rural systems in Maine would divert money away from direct care.

The AHA says 340B has for nearly 35 years helped hospitals stretch limited resources for rural, low-income, and underserved patients, including behavioral health and oncology. A hospital that buys an expensive oral cancer or heart drug at wholesale, then waits on a claim file, needs cash it used to keep in the pharmacy budget. For a system with days, not months, of cash, that gap is a treasury problem even if every rebate later pays in full.

Thin or negative operating margins leave little room to staff a 45-day claims desk, chase denials, and carry wholesale-priced inventory. The four plaintiff hospitals are community providers, not academic medical centers with large treasuries, which is why the association filed in Maine with those names on the caption rather than a national sample of 340B giants.

Judge Walker Vacated the First Pilot in February

The first rebate pilot was built for a January 1, 2026 start and 10 drugs. Hospitals sued in the District of Maine in December 2025. The court that will hear the new case is the court that already stopped version one.

FROM INJUNCTION TO THE SECOND PILOT

1. December 29, 2025: Chief Judge Lance E. Walker issues a preliminary injunction blocking the first 10-drug 340B rebate pilot in the District of Maine.
2. January 2026: The First Circuit refuses to let the pilot start while the appeal is pending, and HHS later drops the appeal. Both the district court and the First Circuit fault HHS for moving ahead without an adequate account of hospital costs.
3. February 10, 2026: Walker grants a joint motion, vacates the August 2025 notices and the 2025 manufacturer approvals, and remands the matter to HRSA.
4. February 2026: HRSA opens a request for information on a rebate model and takes more than 2,400 comments from hospitals, health centers, manufacturers, pharmacies, and patient groups.
5. July 31, 2026: HRSA announces a revised pilot, with manufacturer plans due August 24, 2026, and a January 1, 2027 effective date.
6. August 3, 2026: The revised notice publishes in the Federal Register at 91 FR 48,883.
7. October 9, 2026: The AHA, the Maine Hospital Association, and four hospitals file the new suit and a request for a temporary restraining order.

After the 2025 loss, HHS did not drop the rebate idea. It widened the drug list, added a comment file, wrote payment and resubmission rules, and came back with a January 2027 start. Walsh called that sequence a return to “the same flawed program,” only larger. The legal claim in 2026 is still an Administrative Procedure Act attack: the agency, in the hospitals’ telling, treated cost evidence as optional.

Why HHS Tied Rebates to Medicare Price Talks

HRSA’s case for the pilot is that 340B got too big to police with invoices and after-the-fact audits. The agency said 340B purchases grew from $53.7 billion in 2022 to more than $100 billion in 2025, driven by more covered-entity sites, contract pharmacies, specialty drugs, and overlapping federal price rules.

This revised Pilot helps modernize program oversight by improving visibility into 340B transactions while helping preserve the program’s long-term sustainability for the patients and communities it was created to serve.

Tom Engels, HRSA Administrator, July 31, 2026 statement

A claims rebate, HRSA says, lets a manufacturer see each dispense before it pays, which helps block duplicate discounts that 340B law already forbids and supports the non-duplication rules in the Medicare Drug Price Negotiation Program. That is why the pilot is limited to negotiation-selected drugs during their price-applicability periods, not to the whole 340B catalog. The agency also wants transaction-level data for audits and for a public evaluation due April 30, 2028, after the first year.

Manufacturers have spent years arguing that 340B discounts are stacking on other federal discounts and leaking through contract pharmacies. Hospitals have spent the same years arguing that rebate models are a way to delay payment and harvest claims data. The revised pilot tries to split that fight: manufacturers fund Beacon, HRSA limits the data fields, and rebates cannot be denied for eligibility, diversion, or Medicaid duplicate-discount concerns, which still have to go through HRSA or the statutory audit path.

Hospitals reading that package still see a claims shop they have to staff, a wholesale invoice they have to pay, and a receivable they never carried when the discount sat on the purchase order. HHS reading the same package sees a test on a slice of drugs, a 10-day pay rule, and a comment file it says it already answered. The Maine complaint is the hospitals’ bid to make a judge pick which reading of the cost record counts.

The 10-Day Pay Clock After Each Claim

HRSA limits what a hospital may send to fields such as date of service, NDC-11, quantity, 340B ID, and prescriber or physician ID. Purchasing data and encounter-level data are out. Data collected under the pilot is not supposed to be used for any other purpose, including pooling or licensing. If a rebate is denied, the manufacturer has to document why, and a hospital can take the fight to 340BPricing@hrsa.gov. Rebates also may not be denied because a manufacturer thinks it did not see a matching wholesale purchase.

Those guardrails are the agency’s answer to the 2025 ruling. They do not change the core sequence. A rural hospital still pays wholesale first on drugs such as Eliquis, Jardiance, Ibrance, and Imbruvica, still has 45 days to file, and still waits up to 10 days after a clean file for cash that used to come off the invoice. If the file is dirty, the 10-day clock starts over.

The association asked the Maine court to freeze that sequence before January 1, 2027. Unless the court does, the 21 listed products move to rebates on that date, and HRSA’s first-year test clock starts with them.